Repaglinide restrains HCC development and progression by targeting FOXO3/lumican/p53 axis
Cellular Oncology · 2024-08 · 47 (4) · 1167-1181
DOI: 10.1007/s13402-024-00919-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, online erschienen am 07.02.2024. Verfasst von Yifei Tan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Transplantation Center and Laboratory of Liver Transplantation, West China Hospital of Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Forkhead Box Protein O3, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Liver Transplantation Center and Laboratory of Liver Transplantation, West China Hospital of Sichuan University, Chengdu, China.
- Department of Ultrasonography, West China Second University Hospital, Sichuan University, Chengdu, China.
- Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
- Laboratory of Pathology, Key Laboratory of Transplant Engineering and Immunology, NHC, West China Hospital of Sichuan University, Chengdu, 610041, China.
- Department of Ultrasonography, West China Second University Hospital, Sichuan University, Chengdu, China. luohongcd1969@163.com.
- Department of Liver Transplantation Center and Laboratory of Liver Transplantation, West China Hospital of Sichuan University, Chengdu, China. shiyujun@scu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Tan, Y., Zhou, Y., Zhang, W., Wu, Z., Xu, Q., Wu, Q., Yang, J., Lv, T., Yan, L., Luo, H., Shi, Y., & Yang, J. (2024). Repaglinide restrains HCC development and progression by targeting FOXO3/lumican/p53 axis. Cellular Oncology, 47(4), 1167-1181. https://doi.org/10.1007/s13402-024-00919-9
Vancouver
Tan Y, Zhou Y, Zhang W, Wu Z, Xu Q, Wu Q, et al. Repaglinide restrains HCC development and progression by targeting FOXO3/lumican/p53 axis. Cellular Oncology. 2024;47(4):1167-1181. doi:10.1007/s13402-024-00919-9
BibTeX
@article{Tan2024,
author = {Tan, Yifei and Zhou, Yongjie and Zhang, Wei and Wu, Zhenru and Xu, Qing and Wu, Qiong and Yang, Jian and Lv, Tao and Yan, Lvnan and Luo, Hong and Shi, Yujun and Yang, Jiayin},
title = {Repaglinide restrains HCC development and progression by targeting FOXO3/lumican/p53 axis},
journal = {Cellular Oncology},
year = {2024},
volume = {47},
number = {4},
pages = {1167--1181},
doi = {10.1007/s13402-024-00919-9}
}
EUVIMED